Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical app ...

The ability to achieve complete IRAK4 degradation and cytokine suppression in disease-relevant tissues such as synovial ... superior therapeutic benefits for chronic inflammatory diseases including ...

Evommune launches mid-stage trials for immune-modulating drugs targeting skin conditions, backed by $115M funding and led by ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

A Q&A between Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, and Managed Healthcare Executive about new discoveries in chronic itch, how ...

J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...

Explore holistic approaches to treating the atopic triad in children—eczema, asthma, and allergies—with naturopathic ...

Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious ...

There are many types of rash that can develop on the buttocks. Examples include heat rash, acne, dermatitis, and genital herpes. A rash can cause itching or irritation, inflamed bumps or dots on ...

placebo (95%CI：9.27~74.62). In the higher dose group, 41.7% of patients (5/12) achieved a validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™) score of 0 (clear) or 1 (almost ...